2022 Fiscal Year Final Research Report
Validation of risk classification using the novel neuroblastoma marker 3-MTS
| Project/Area Number |
21K20833
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
0901:Oncology and related fields
|
|---|
| Research Institution | Nagoya University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2021-08-30 – 2023-03-31
|
| Keywords | 3methoxytyramine sulfate / 高リスク神経芽腫 |
|---|
| Outline of Final Research Achievements |
We established a quantitative method for 3-methoxytyramine sulfate (MTS), which contributes significantly to the growth of neuroblastoma, and determined reference values. The AUC, sensitivity, and specificity of each metabolite for neuroblastoma diagnosis were HVA (AUC 0.974, sensitivity 87.9%, specificity 96.2%), VMA (AUC 0.963, sensitivity 90.9%, specificity 96.2%), and MTS (AUC 0.989, sensitivity 93.9%, specificity 94.9%). MTS showed the potential to effectively identify high-risk neuroblastoma (high-risk vs. intermediate-low-risk) compared to existing markers. (HVA: AUC=0.613, VMA: AUC=0.590, MTS: AUC=0.808)
|
| Free Research Field |
小児外科
|
| Academic Significance and Societal Importance of the Research Achievements |
神経芽腫治療は、ここ数十年大量化学療法/自家造血幹細胞移植/免疫療法（抗GD2抗体）などの治療が進歩しても、未だに劇的な予後改善に繋がる診断治療法はない。これまで神経芽腫の予後改善に直結する治療前リスク判別マーカー及びモニタリングマーカーが望まれてきた。腫瘍マーカーで治療前リスクを判別できれば、リスクに応じた適切な治療を行えるため、複雑な病態を呈する神経芽腫において治療前リスク判別マーカーの利用価値は非常に高い。神経芽腫は歴史的に尿中代謝物の解析と病態との解析が進んでおり、MTS臨床使用の実現性は非常に高いと考える。
|
